CHINOOK THERAPEUTICS, INC. Inactive Instrument
Chinook Therapeutics, Inc.
Equities
KDNY
US16961L1061
Biotechnology & Medical Research
Presenter SpeechJoseph Schwartz (Analysts)Hello. Welcome to this fireside chat with Chinook Th...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase III trials for the treatment of IgA nephropathy (IgAN) and proteinuric glomerular diseases. Its second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in Phase II development for patients with IgAN. Its third product candidate, CHK-336, is an oral small molecule lactate dehydrogenase (LDHA), inhibitor for the treatment of primary and idiopathic hyperoxaluria that is in a Phase I clinical trial in healthy volunteers. In addition, the Company is also conducting research programs in several other rare, severe chronic kidney diseases.
| 1st Jan change | Capi. | |
|---|---|---|
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
